Loading
Tryptophan and Brain Disorders · Journal article
BMC Psychiatry · July 29, 2026
Encouraging direction, but not yet definitive.
This prospective observational study reports that plasma sphingosine-1-phosphate and its receptors (S1PR1, S1PR3) are elevated in MDD compared to healthy controls, decrease with 8-week antidepressant treatment, and show sex-specific patterns. Baseline S1P predicts symptom improvement and the three-marker panel achieves high diagnostic discrimination (AUC 0.9575), but the uncontrolled design, lack of randomization, and single-site sample limit strength and require independent replication.
Prospective observational cohort study with baseline and 8-week post-treatment assessment. Patients with major depressive disorder (n=56) and healthy controls (n=42). Specific inclusion/exclusion criteria, age range, treatment history, and comorbidities not stated.. Intervention: 8-week antidepressant treatment protocol (specific medications and regimen not detailed in abstract).. Compared with: Healthy controls at baseline; within-group pre-post comparison for treatment effect.. n = 98. Not stated..
Plasma S1P, S1PR1, and S1PR3 significantly elevated in MDD at baseline compared to healthy controls. All three markers significantly decreased after 8 weeks of antidepressant treatment and trended toward normal levels. Baseline S1PR1 and S1PR3 elevations more pronounced in female than male patients.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated in larger, independent cohorts with randomized design, S1P and its receptors could serve as objective biomarkers to aid MDD diagnosis and predict treatment response, potentially reducing reliance on subjective assessment. The sex-specific findings suggest biomarker thresholds may require sex adjustment. However, the single-centre, uncontrolled design and modest sample preclude clinical deployment or practice change at this stage.
A single-centre, uncontrolled observational study with modest sample size (n=56 MDD patients) showing biomarker changes in response to treatment and diagnostic discrimination, but lacking a randomized comparator arm and requiring external validation before clinical deployment.
As stated by the source record.
Quoted from the source exactly as published.
If validated in larger, independent cohorts with randomized design, S1P and its receptors could serve as objective biomarkers to aid MDD diagnosis and predict treatment response, potentially reducing reliance on subjective assessment. The sex-specific findings suggest biomarker thresholds may require sex adjustment. However, the single-centre, uncontrolled design and modest sample preclude clinical deployment or practice change at this stage.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: The diagnosis of major depressive disorder (MDD) currently relies on subjective clinical assessments, highlighting a critical need for objective biological markers. The sphingosine-1-phosphate (S1P) signaling pathway, a pivotal regulator of neuro-immune interactions, has emerged as a potential contributor to MDD pathophysiology, yet its role remains incompletely understood. This study aimed to investigate plasma levels of S1P and its key receptors, S1PR1 and S1PR3, as potential diagnostic and predictive biomarkers for MDD, with a specific focus on sex differences and treatment effects. METHODS: Patients with MDD (n = 56) underwent an 8-week treatment protocol were enrolled, alongside 42 healthy controls (HCs). Depression severity was evaluated using the Hamilton Depression Rating Scale (HAMD-24) and Patient Health Questionnaire (PHQ-9) at baseline and 8-week visit. The plasma levels of S1P, S1PR1 and S1PR3 were measured at baseline and week 8. RESULTS: At baseline, plasma concentrations of S1P, S1PR1, and S1PR3 were significantly elevated in patients with MDD compared to HCs. All three markers significantly decreased and trended toward normal levels after 8 weeks of antidepressant treatment. Notably, a significant sex-specific difference was observed for the receptors, baseline elevations of S1PR1 and S1PR3 were more obvious in female patients than in male patients. Furthermore, baseline S1P levels significantly predicted symptom improvement-as measured by changes in both HAMD-24 and PHQ-9 scores-whereas baseline S1PR levels alone did not. In addition, a combined panel of S1P, S1PR1, and S1PR3 yielded high diagnostic accuracy, with an area under the receiver operating characteristic curve (AUC) of 0.9575. CONCLUSION: Our data demonstrate a significant, sex-dependent dysregulation of the peripheral S1P signaling pathway in MDD, which is responsive to antidepressant treatment. The ability of baseline S1P to predict clinical outcomes and the encouraging diagnostic precision of the S1P-S1PR1-S1PR3 panel strongly support their potential as clinically applicable biomarkers. These results imply that the S1P pathway plays a crucial role in the pathophysiology of depression, offering new possibilities for diagnosis and personalized treatment strategies in psychiatry.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.